WO1998015288A1 - Vaccine composition containing as additive a sympathomimetic compound - Google Patents
Vaccine composition containing as additive a sympathomimetic compound Download PDFInfo
- Publication number
- WO1998015288A1 WO1998015288A1 PCT/FR1997/001759 FR9701759W WO9815288A1 WO 1998015288 A1 WO1998015288 A1 WO 1998015288A1 FR 9701759 W FR9701759 W FR 9701759W WO 9815288 A1 WO9815288 A1 WO 9815288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- adjuvant
- acid
- compound
- surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Definitions
- the present invention relates to new adjuvants for vaccine compositions as well as compositions comprising at least one antigen, in particular an antigen of viral, bacterial or parasitic origin and at least one adjuvant.
- adjuvants in the compositions has been known for a long time.
- the main purpose of these adjuvants is to increase the immune response.
- These adjuvants are of various natures. They may for example consist of liposomes, emulsions comprising at least one oil phase and at least one aqueous phase, of the Freund adjuvant type or, more commonly in mineral salts insoluble in water. These mineral salts can constitute, for example in aluminum hydroxide, a cerium nitrate, zinc sulphate, colloidal iron hydroxide or calcium chloride. Aluminum hydroxide is the most commonly used adjuvant. These adjuvants are described in particular in the article by Rajesh K. Gupta et al "Adjuvants, balance between toxicity and adjuvanticity", Vaccine, vol. 1 1, Issue 3, 1993, pages 993-306.
- the Applicant has therefore sought to develop substances capable of modulating and / or transiently increasing the level of intracellular messengers, such as cAMP, in order to increase the immune response without thereby inducing toxicity vis-à-vis the subjects treated.
- the subject of the invention is a composition comprising: (i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence; and, (ii) at least one adjuvant, characterized in that said adjuvant comprises at least one sympathomimetic compound.
- antigenic subunits can be, for example, a protein, a glycoprotein, a peptide, or a recombinant virus, in particular a non-enveloped virus such as adenoviruses, vaccinia virus, Canarypox virus, herpes viruses, baculoviruses; a non-enveloped living viral recombinant vector is also designated, the genome of which contains, preferably inserted into a part which is not essential for the replication of the corresponding enveloped virus, a sequence coding for an antigenic subunit inducing antibody synthesis and / or a protective effect against the above enveloped virus or pathogenic microorganism; these antigenic subunits can be, for example, a protein, a glycoprotein, a peptide, or
- the aim of this last nucleotide sequence is to allow the expression of a compound comprising an amino acid sequence, this compound itself having the aim of triggering an immune reaction in a host organism;
- sympathomimetic compounds is meant in particular amphetamines, catecholamines, phenylisopropylamines or tyramine.
- isoproterenol L-epinephrine, levarterenol, ephedrine, phenylephedrine or salbutamol.
- the latter also relates to a composition as defined above comprising, in addition, at least one pharmaceutically acceptable salt which is soluble in water, said salt consisting of an organic anion and of a metal cation.
- a water-soluble salt within the meaning of the present invention can be such that its solubility in water is greater than or equal to 10 g / l and, preferably, between 10 and 2000 g / l.
- the metal cation constituting said pharmaceutically acceptable salt is preferably a bivalent cation, advantageously this cation is a cation of a metal chosen from the group consisting of manganese, calcium and zinc.
- Manganese is a metal which is very particularly preferred in the context of the present invention.
- the organic anion constituting said pharmaceutically acceptable salt is advantageously an anion of a compound comprising at least one oxygen-containing functional group, preferably a phosphoric group or a carboxylic group.
- Glycerophosphoric acid is a group anion preferred phosphoric.
- the anions comprising at least one preferred carboxylic group are derived from compounds chosen from: acid oses, preferably acid oses having from 5 to 7 carbon atoms, more preferably those having 6 to 7 carbon atoms, mono or polycarboxylic acids, amino acids.
- the preferred mono or polycarboxylic acids are fumaric acid or the compounds of formula (I)
- R represents COOH, CHaCO, CHa or CH2OH
- R ' represents H or COOH and s, t and u, which are identical or different, are between 0 and 3.
- Preferred compounds of formula (I) are acetic acid, lactic acid, tartaric acid, malic acid, citric acid, pyruvic acid.
- an acidic ose consists of an ose comprising at least one carboxylic function, a ose being a carbohydrate constituted by the reducing sugars.
- These acid oses are advantageously derivatives of aldoses, obtained by oxidation of the primary alcohol function or of the aldehyde function into a carboxylic function.
- Such compounds may very particularly consist of gluconic acid, glucuronic acid, fructoheptonic acid, gluconoheptonic acid, glucoheptonic acid.
- the organic anion is a derivative of an amino acid, this amino acid can be an ⁇ -amino acid such as glutamic acid, methionine and, very particularly, aspartic acid.
- a pharmaceutically acceptable salt, soluble in water according to the invention can comprise a polyvalent cation, in particular divalent, associated with an organic anion or with several organic anions of nature. different.
- a bivalent cation such as the calcium cation can be associated with an anion derived from gluconoheptonic acid.
- a composition thus defined contains between 0.02 and 3000 mg / ml, preferably 0.1 and 1000 mg / ml of the mineral salt and, in particular, between 0.1 and 150 mg / ml.
- the composition as defined above can also contain an oil.
- the composition according to the invention is advantageously in the form of an emulsion associating at least one aqueous phase and at least one oil phase.
- This emulsion can be of the oil in water (O / W), water in oil (W / O), water in oil in water (W / O / W) or microemulsion type.
- W / O / W and O / W emulsions are preferred.
- Such an emulsion can be prepared according to the conventional methods for preparing an emulsion, in particular according to the methods described in patent applications EP-A-489,181 and EP-A-481,982.
- the emulsion can be emulsified with stirring. constituent oil of the oil phase with the aqueous phase consisting of an aqueous solution or suspension containing the antigen.
- An emulsion according to the invention can comprise, by weight, from 5 to 95% of oil phase for 95 to 5% of aqueous phase and, preferably, from 25 to 75% of oil phase for 75 to 25% of aqueous phase.
- the emulsion should preferably be stable for at least 12 months when it is stored at 4 ° C.
- the oils, consisting of said oily phase which can be used in the composition according to the invention are advantageously fluid oils chosen from natural or synthetic mineral oils, or non-mineral oils of vegetable, animal or synthetic origin known for their absence or their low toxicity.
- oils must be liquid at storage temperature (+ 4 ° C) or at least give liquid emulsions at this temperature.
- straight chain mineral oils having a number of carbon atoms preferably greater than 16 and free of compounds will be chosen. aromatic.
- MARCOL 52 and DRAKEOL 6VR Synthetic oils such as polyisobutenes or polyisopropenes can also be used.
- unsaturated oils rich in oleic acid which are biodegradable will be chosen, for example peanut, olive, sesame, soybean or wheat germ oils.
- animal oils the same criteria of tolerance and immune efficacy are required. By way of example as animal oils, mention may be made of squalane or spermaceti oil.
- composition according to the invention when it is in the form of an emulsion as defined above, can also advantageously comprise one or more emulsifying surfactants.
- the latter has a lipophilic or hydrophilic character characterized by an HLB (hydrophilic-lipophilic-balance) value of between 1 and 19.
- HLB hydrophilic-lipophilic-balance
- Ra represents a saturated, linear or branched aliphatic radical, comprising from 4 to 24 carbon atoms
- Z is the remainder of a sugar, preferably the glucose and n is between 1 and 5, preferably between 1, 1 and 2.
- polyoxyethylated alkanols such as those sold under the designation BRU by the company ICI
- - polymers comprising polyoxyethylene and polyoxypropylene blocks such as those sold under the designation PLURONICS by the company BASF.
- Particularly preferred surfactants are polyethylene glycol esters, obtained by condensation of a fatty acid, in particular a liquid fatty acid at 20 ° C. with a polyethylene glycol of molecular weight between 80 and 200; such a surfactant is sold by the company SEPPIC under the brand SIMULSOL 2599.
- Another preferred surfactant in the context of the present invention consists of an ester obtained by condensation of a fatty acid, advantageously a fatty acid which is liquid at 20 ° C. with a sugar, sorbitol or glycerol.
- Said sugar can consist of glucose, sucrose or, preferably, mannitol.
- mannitol ester there may be mentioned mannitol oleates obtained by anhydrization of the polyhydroxylated carbon chain of mannitol which cyclizes in 1-4 or 2-6.
- Derivatives of these polyethylene glycol, sorbitol or glycerol sugar esters can also be used. These derivatives exhibit modified hydrophilicity in particular by grafting hydrophilic functions such as alcohol, polyol, ethylene oxide, propylene oxide, carboxylic acid, amine or amide. Such derivatives may for example consist of fatty esters of polyoxyethylated sorbitan, such as TWEEN.
- the other types of preferred surfactants consist of ethoxylated vegetable oils, such as, for example polyethoxylated castor oil, this oil being hydrogenated or not, or polyglycerol esters, in particular polyglycerol esters of natural fatty acids such as oleic acid, stearic acid, ricinoleic acid or isostearic acid and, in particular, ricinoleates or polyricinoleates of polyglycerol.
- a surfactant according to the invention is preferably pharmaceutically acceptable in the mucous membranes; it must in particular be free of heavy metals and have very low acid or peroxide indices.
- the surfactant is combined with the oily adjuvant before the emulsion is formed.
- concentration of surfactant in the composition as defined above can be between 0.01 and 500 mg / ml, and preferably between 0.1 and 200 mg / ml.
- Oils associated with a surfactant which are very particularly suitable in the context of the present invention are those sold by the company SEPPIC under the brand MONTANIDE.
- the nature of these oils, the type of emulsion which they make it possible and the characteristics (viscosity and conductivity) of these emulsions are described in the international application WO94 / 1 6681, published on August 4, 1994 and, in particular, page 1 1, Table I.
- These compositions according to the invention can be used for the treatment of human or veterinary diseases. In particular, they make it possible to relieve infectious diseases with an intracellular agent, in particular respiratory diseases, opportunistic infectious diseases and, within the framework of veterinary medicine, infectious diseases of fish.
- the composition according to the invention can also contain substances which modulate immunity.
- the oily adjuvant can also consist of a self-emulsifying oil, that is to say an oily preparation capable of forming a stable emulsion with an aqueous phase, practically without any energy supply, for example by dispersion in the aqueous phase by agitation slow mechanical.
- a self-emulsifying oil that is to say an oily preparation capable of forming a stable emulsion with an aqueous phase, practically without any energy supply, for example by dispersion in the aqueous phase by agitation slow mechanical.
- self-emulsifying oils as known in the European pharmacopoeia under the designations Labrafil and Simulsol. These oils are polyglycosylated glycerides.
- Preferred self-emulsifiable oils are those described in French patent application No. 9500497 filed on January 18, 1995, in the name of the Applicant, entitled “use of ethoxylated fatty acid esters as self-emulsifiable components, in particular useful for the preparation of phytosanitary compositions or drugs for veterinary or human use ", the reference of which is incorporated into the present description.
- These oils consist of esters of ethoxylated fatty acids corresponding to one of the following formulas:
- R3, R5, R6, R ⁇ and R 10 represent a hydrocarbon chain, linear or branched, saturated or unsaturated having from 5 to 30 carbon atoms;
- - R2 'F * 4' ⁇ 7 and ⁇ 9 represent a hydrocarbon chain, linear or branched, saturated or unsaturated having from 1 to 5 carbon atoms;
- the total number of ethylene oxide molecules respectively represented in the aforementioned formulas II, III and IV by k, l + m, n + p + q being an integer such as the HLB (hydrophilic-lipophilic balance) value of said said said compounds is between about 4 and about 10, preferably between about 5 and about 9.
- R- ⁇ is preferably chosen from the residues of palmitic, stearic, ricinoleic, oleic, linoleic and linolenic acids and R2 represents a methyl radical and k is an integer between 1 and
- the preferred ethoxylated fatty acid esters of formula III are those where:
- R ⁇ , R ⁇ and R 10 represent hydrocarbon chains having from 16 to 22 carbon atoms corresponding in particular to the fatty chains of rapeseed oil, corn, soybean, peanut and apricot kernels;
- R7 and R9 represent a methylene group CH2;
- R7 and R9 represent a methylene radical CH2;
- the concentration of self-emulsifiable oil in the composition according to the invention can be between approximately 5 and 700 g / l, preferably between approximately 10 and 500 g / l.
- the composition according to the invention can comprise a conventional immune stimulating agent.
- a conventional immune stimulating agent such as Avridine®, ie N, N-dioctadecyl-N ', N' - bis (2-hydroxyethyl) propanediamine, derivatives of MDP (muramyl dipeptide), in particular threonyl-MDP, derivatives of mycolic acid or Lipid A derivatives.
- the composition according to the invention may also comprise one or more surfactants, in the absence of any oily adjuvant.
- composition is then presented in the form of a micellar solution.
- This can be prepared by simple mixing of the surfactant with a dispersion in water of the antigen or of the antigen generator in vivo.
- the surfactant can be chosen from the surfactants described above, in combination with an oily adjuvant.
- Said micellar solution can comprise from 0.5 to 500 mg / ml, preferably from 1 to 250 mg / ml as a surfactant.
- a composition according to the present invention can comprise an antigen such as a virus, a microorganism, more particularly a bacterium or a parasite, or a compound comprising a peptide chain.
- an antigen such as a virus, a microorganism, more particularly a bacterium or a parasite, or a compound comprising a peptide chain.
- a compound may consist of a protein or a glycoprotein, in particular a protein or a glycoprotein derived from a microorganism, a synthetic peptide or a protein or peptide derived from genetic engineering. Said viruses and microorganisms can be totally inactivated or live attenuated.
- viruses which may constitute an antigen according to the present invention mention may be made of the rabies virus, herpesviruses such as Aujeszky's disease virus, orthomixoviruses such as Influenzae, picornaviruses such as fever virus foot and mouth disease or retroviruses such as HIV.
- herpesviruses such as Aujeszky's disease virus
- orthomixoviruses such as Influenzae
- picornaviruses such as fever virus foot and mouth disease or retroviruses
- retroviruses such as HIV.
- a microorganism of the bacterial type which can constitute an antigen according to the present invention mention may be made of E. coli, and those of the genera Pasteurella, Furonculosis, Vibriosis, Staphylococcus and Streptococcus.
- a parasite mention may be made of those of the genera Trypanosoma, Plasmodium and Leishmania.
- a composition according to the invention comprises an antigen concentration which depends on the nature of this antigen and on the nature of the subject treated. It is however particularly remarkable that an adjuvant according to the invention, associated or not with an oily adjuvant and / or a surfactant as defined above, makes it possible to significantly reduce the usual dose of antigen required.
- the appropriate concentration of antigen can be determined conventionally by those skilled in the art. Generally, this dose is of the order of 0.1 ⁇ g / ml to 1 g / ml more generally between 1 ⁇ g / ml and 100 mg / ml.
- a composition according to the invention can also comprise an in vivo generator of a compound comprising an amino acid sequence, that is to say a biological compound capable of expressing such a compound in the host organism in which one introduced said generator in vivo.
- the compound comprising the amino acid sequence can be a protein, a peptide or a glycoprotein.
- they can consist of living microorganisms, generally a virus, playing the role of recombinant vector, into which is inserted a nucleotide sequence, in particular an exogenous gene.
- a virus playing the role of recombinant vector, into which is inserted a nucleotide sequence, in particular an exogenous gene.
- These compounds are known as such and used in particular as a recombinant unitary vaccine.
- the microorganism constituting a recombinant subunit vaccine is a non-enveloped recombinant virus, for example chosen from adenoviruses, vaccinia virus, canarypox virus, herpes viruses or baculoviruses.
- the exogenous gene inserted into the microorganism can be, for example, from an Aujeszky or HIV virus.
- the in vivo generators according to the invention can also consist of a recombinant plasmid comprising an exogenous nucleotide sequence, capable of expressing in a host organism a compound comprising an amino acid sequence.
- the compound comprising the amino acid sequence which is expressed within the host organism can:
- the in vivo generator allows treatment of the host, of the gene therapy type.
- a curative action may consist in a synthesis by the in vivo cytokine generator, such as interleukins, in particular interleukin 2.
- the concentration of said generator in vivo in the composition according to the invention again depends, in particular, on the nature of said generator and on the host in which it is administered. This concentration can be easily determined by a person skilled in the art, on the basis of routine experience.
- the generator in vivo when the generator in vivo is a recombinant microorganism, its concentration in the composition according to the invention can be between 10 2 and 10 15 microorganisms / ml, preferably between 10 5 and 10 12 microorganisms / ml.
- the in vivo generator is a recombinant plasmid, its concentration in the composition according to the invention can be between 0.01 and 100 g / l.
- a composition according to the invention can be used as a preventive or curative medicament.
- a composition according to the invention can be administered to fish, crustaceans such as shrimps, poultry, in particular, geese, turkeys, pigeons and chickens, canines such as dogs, felines such as cats, pigs, primates, bovines, ovids and horses.
- the composition according to the invention comprising at least one sympathomimetic compound as defined above, can also be administered to humans.
- the administration of the composition can be carried out in a conventional manner by parenteral route, in particular by subcutaneous, intramuscular or intraperitoneal injection or by mucosal route in particular by oral route, rectal route, nasal route, vaginal route.
- an adjuvant consisting of a sympathomimetic compound as defined above for the preparation of a vaccine intended for the prevention or treatment of a disease infectious, including an infectious disease caused by a virus or microorganism such as those mentioned above.
- this adjuvant for the preparation of a composition intended to treat a functional disease, such as cancer or cystic fibrosis.
- said adjuvant can be combined with a pharmaceutically acceptable salt, soluble in water and / or with an oily adjuvant, a surfactant or with an oily adjuvant itself associated with a surfactant; these oily adjuvants and surfactants being as defined above.
- Adjuvant compositions comprising said sympathomimetic compound, said pharmaceutically acceptable salt and the oily adjuvant and / or the aforementioned surfactants constitute yet another aspect of the invention. Where appropriate, these adjuvant compositions comprising at least one aqueous phase.
- the adjuvant compositions according to the invention comprising at least one oily adjuvant, and, if necessary, a surfactant, can be in the form of an emulsion.
- the latter can be of the W / O, O / W, W / O / W or microemulsion type.
- These emulsions can comprise by weight, from 0.5% to 99.5
- % of oil phase for 99.5% to 0.5% of aqueous phase preferably from 5 to 95% of oil phase for 95 to 5% of aqueous phase and, more preferably, from 25 to 75% of oil phase for 75 to 25% of aqueous phase. If necessary, they can comprise from 0.01 to 500 mg / ml, preferably from 0.1 to 200 mg / ml of at least one surfactant.
- the adjuvant composition according to the invention comprises, in addition to the sympathomimetic compound, optionally the pharmaceutically acceptable salt and an aqueous phase, only one or more surfactants, it is then in the form of a micellar solution.
- the surfactant content of this micellar solution can be between 0.01 and 900 mg / ml, preferably between 1 and 250 mg / ml.
- An adjuvant composition according to the invention usually comprises the sympathomimetic compound at a concentration of 10 "10 molar to 10 " 2 molar, preferably from 10 "7 Molar to 10 " 5 Molar. When it contains a pharmaceutically acceptable salt as defined above, it is at a concentration of 0.02 to 3000 mg / ml, preferably 0.1 to 1000 mg / ml, more preferably from 0.1 to 150 mg / ml.
- compositions are useful for preparing the compositions according to the invention.
- the latter can then be prepared by simple mixing of the adjuvant composition with a composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence.
- a composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence can then be prepared by simple mixing of the adjuvant composition with a composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence.
- the first step before testing the adjuvant potential of ⁇ -adrenergic agonists was the demonstration of the receptor on cells involved in mucosal immunity, especially in cholera toxin target cells in the intestinal mucosa. of the mouse and the demonstration of the functional coupling of this receptor to its effector the enzyme adenylate cyclase.
- enterocytes MODE-K cell line
- PEYER plaque lymphocytes LPP
- mesenteric lymph nodes LGM
- intraepithelial lymphocytes LEL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97943940A EP0946194A1 (en) | 1996-10-07 | 1997-10-03 | Vaccine composition containing as additive a sympathomimetic compound |
AU45600/97A AU4560097A (en) | 1996-10-07 | 1997-10-03 | Vaccine composition containing as additive a sympathomimetic compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/12191 | 1996-10-07 | ||
FR9612191A FR2754182B1 (en) | 1996-10-07 | 1996-10-07 | NOVEL VACCINE COMPOSITIONS COMPRISING AS ADJUVANT A SYMPATHOMIMETIC COMPOUND |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998015288A1 true WO1998015288A1 (en) | 1998-04-16 |
Family
ID=9496418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1997/001759 WO1998015288A1 (en) | 1996-10-07 | 1997-10-03 | Vaccine composition containing as additive a sympathomimetic compound |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0946194A1 (en) |
AU (1) | AU4560097A (en) |
FR (1) | FR2754182B1 (en) |
WO (1) | WO1998015288A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1095662A1 (en) | 1999-10-29 | 2001-05-02 | Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C. | New vaccine composition and use of surfactants as immuno-adjuvant |
WO2011092412A1 (en) | 2010-02-01 | 2011-08-04 | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC | Use of a specific mineral oil for the production of a novel adjuvant |
WO2011092413A1 (en) | 2010-02-01 | 2011-08-04 | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC | Adjuvant for the preparation of vaccine compositions intended for the prevention of coccidiosis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2809961B1 (en) * | 2000-06-09 | 2004-12-03 | Seppic Sa | USE OF SUGAR ETHERS AS IMMUNITY ADDITIVES IN VACCINE COMPOSITIONS, THERAPEUTIC COMPOSITIONS CONTAINING THEM AND THEIR USE AS VACCINES |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0445710A1 (en) * | 1990-03-08 | 1991-09-11 | BEHRINGWERKE Aktiengesellschaft | Use of zinc-calcium hydroxyde, lecithin and PAO for adjuvating antigen solutions and antigen solutions adjuvated in this way |
WO1994016681A1 (en) * | 1993-01-29 | 1994-08-04 | Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C | Recombinant living subunit vaccine composition and process for its preparation |
WO1995025542A1 (en) * | 1994-03-22 | 1995-09-28 | Societe D'exploitation De Produits Pour L'industrie Chimique, S.E.P.P.I.C. | Composition including a recombinant plasmid, and uses thereof as a vaccine and drug |
WO1996022109A1 (en) * | 1995-01-18 | 1996-07-25 | Societe D'exploitation De Produits Pour Les Industries Chimiques - Seppic | Utilization of ethoxylated fatty acid esters as self-emulsifiable compounds |
WO1996032964A1 (en) * | 1995-04-20 | 1996-10-24 | Societe D'exploitation De Produits Pour Les Industries Chimiques-Seppic | Therapeutic composition comprising an antigen or an in vivo generator for generating a compound comprising an amino acid sequence |
-
1996
- 1996-10-07 FR FR9612191A patent/FR2754182B1/en not_active Expired - Fee Related
-
1997
- 1997-10-03 WO PCT/FR1997/001759 patent/WO1998015288A1/en not_active Application Discontinuation
- 1997-10-03 EP EP97943940A patent/EP0946194A1/en not_active Withdrawn
- 1997-10-03 AU AU45600/97A patent/AU4560097A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0445710A1 (en) * | 1990-03-08 | 1991-09-11 | BEHRINGWERKE Aktiengesellschaft | Use of zinc-calcium hydroxyde, lecithin and PAO for adjuvating antigen solutions and antigen solutions adjuvated in this way |
WO1994016681A1 (en) * | 1993-01-29 | 1994-08-04 | Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C | Recombinant living subunit vaccine composition and process for its preparation |
WO1995025542A1 (en) * | 1994-03-22 | 1995-09-28 | Societe D'exploitation De Produits Pour L'industrie Chimique, S.E.P.P.I.C. | Composition including a recombinant plasmid, and uses thereof as a vaccine and drug |
WO1996022109A1 (en) * | 1995-01-18 | 1996-07-25 | Societe D'exploitation De Produits Pour Les Industries Chimiques - Seppic | Utilization of ethoxylated fatty acid esters as self-emulsifiable compounds |
WO1996032964A1 (en) * | 1995-04-20 | 1996-10-24 | Societe D'exploitation De Produits Pour Les Industries Chimiques-Seppic | Therapeutic composition comprising an antigen or an in vivo generator for generating a compound comprising an amino acid sequence |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1095662A1 (en) | 1999-10-29 | 2001-05-02 | Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C. | New vaccine composition and use of surfactants as immuno-adjuvant |
WO2011092412A1 (en) | 2010-02-01 | 2011-08-04 | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC | Use of a specific mineral oil for the production of a novel adjuvant |
WO2011092413A1 (en) | 2010-02-01 | 2011-08-04 | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC | Adjuvant for the preparation of vaccine compositions intended for the prevention of coccidiosis |
Also Published As
Publication number | Publication date |
---|---|
AU4560097A (en) | 1998-05-05 |
EP0946194A1 (en) | 1999-10-06 |
FR2754182A1 (en) | 1998-04-10 |
FR2754182B1 (en) | 1998-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0825875B1 (en) | Therapeutic composition comprising an antigen or an in vivo generator for generating a compound comprising an amino acid sequence | |
EP0480982B2 (en) | Vaccines and vectors with liquid active principles containing an oil which can be metabolised | |
EP0681470B1 (en) | Recombinant living subunit vaccine composition and process for its preparation | |
FR2922767A1 (en) | PROCESS FOR PREPARING A VACCINE COMPOSITION COMPRISING AT LEAST ONE ANTIGEN AND AT LEAST ONE ADJUVANT | |
EP0751788B1 (en) | Composition including a recombinant plasmid, and uses thereof as a vaccine and drug | |
EP0939649B1 (en) | Additive, in particular in the form of an emulsion containing a trivalent metal cation and vaccine composition containing same | |
EP0946194A1 (en) | Vaccine composition containing as additive a sympathomimetic compound | |
EP1095662B1 (en) | New vaccine composition and use of surfactants as immuno-adjuvant | |
FR2814956A1 (en) | Vaccine compositions prepared by freezing distinct phases to keep the antigen and the adjuvant separate, have greater storage stability than those frozen as a single phase. | |
EP1385475A2 (en) | Immunity adjuvant containing a complexed metal cation and vaccine containing same | |
EP1387669A1 (en) | Concentrated w/o emulsion | |
EP2531215B1 (en) | Use of a specific mineral oil for the production of a novel adjuvant | |
EP1163909B1 (en) | Use of sugar ethers as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccine | |
EP1397122B1 (en) | Solid immunity adjuvant and vaccine containing the same | |
FR2824269A1 (en) | Adjuvant composition for use in injectable compositions, especially vaccines, comprising oil and surfactants with specific HLB value, providing high fluidity and good storage stability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997943940 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997943940 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997943940 Country of ref document: EP |